Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center.

According to data from a retrospective analysis of the patient population from the phase 3 CALGB/SWOG 80405 trial (NCT00265850), patients with mCRC with high HER2 expression experienced progression-free survival (PFS) and overall survival (OS) benefit regardless of treatment with bevacizumab (Avastin) or cetuximab (Erbitux). Notably, the association between HER2 expression and survival outcomes was nonlinear, with increases in OS, PFS, and overall response rate plateauing after reaching the median value of HER2 expression. Furthermore, the study found that among patients with high HER2 expression, treatment with cetuximab plus chemotherapy was associated with improved OS vs bevacizumab plus chemotherapy. Conversely, patients with low HER2 expression achieved superior PFS and OS with the bevacizumab regimen vs the cetuximab regimen.

In our exclusive interview, Lenz discussed critical gaps in knowledge regarding the role of HER2 expression in mCRC, expanded on the link between HER2 expression and responses with bevacizumab- vs cetuximab-based regimens, and emphasized the potential utility of HER2 expression to guide treatment decision-making in this setting.


That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Chun Chao, PhD, MS
Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2
Richard Kim, MD
Salman R. Punekar, MD
Chun Chao, PhD, MS
Christos Kyriakopoulos, MD
Marwan G. Fakih, MD
John L. Marshall, MD
Rene Adam, MD, PhD
Amin Nassar, MD